Press releases

July 2021

SynAct Pharma Appoints Anders Dyhr Toft, MD, Ph.D., as Chief Medical Officer

SynAct Pharma AB (“SynAct”) today announced the appointment of Anders Dyhr Toft, MD, PhD, as Chief Medical Officer (CMO), effective August 1, 2021. He will head up clinical development and medical aff... Read more

SynAct Pharma AB Announces Additional Data from the Phase 2a Trial of AP1189 in Covid-19 Infected Patients and Reminds of Management Call to Discuss Results

SynAct Pharma AB (“SynAct”) today announced additional results from all treated patients in the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency.  The study was ... Read more

SynAct Pharma Hosts Conference Call on Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

SynAct Pharma AB ("SynAct") today announced it will host a conference call on July 7 at 13:00 CEST focused on the positive topline results from the Phase 2a clinical trial of AP1189 in Covid-19 infected... Read more

June 2021

SynAct Pharma AB Announces Positive Data from a Phase 2a Trial of AP1189 in Covid-19 Infected Patients

SynAct Pharma AB ("SynAct") today announced topline results from the Phase 2a clinical trial of AP1189 in Covid-19 infected patients with pulmonary insufficiency.  Patients treated with 100mg AP1189 orally ... Read more

SynAct Pharma Files Patent Applications Related to AP1189 Derived APIs and Oral Formulations

June 23, 2021 SynAct Pharma AB (“SynAct”) today announces that the company has filed two patent applications covering novel salt and crystal forms related to AP1189 and the oral delivery of AP1189 and... Read more

SynAct Pharma completes recruitment and dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients

SynAct Pharma AB ("SynAct") today announced that dosing in part 2 of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been completed.... Read more

May 2021

Bulletin from the annual general meeting in SynAct Pharma AB on 21 May 2021

Today, on 21 May 2021, the annual general meeting was held in SynAct Pharma AB. In light of the ongoing Covid-19 pandemic and in order to reduce the risk of infection spreading, the annual general meeting... Read more

Synact Pharma to present at upcoming investor conference

Synact Pharma, today announces that members of its executive management team is invited to present at upcoming conference.: ABGSC Life Science Summit, virtual Date: 25 May 2021 Presenter: Dr. Torbjørn ... Read more

SynAct Pharma AB: SynAct Pharma initiates collaboration on pharmacogenetic aspects of AP1189 compound in Rheumatoid arthritis with Barts and London School of Medicine, Queen Mary University of London.

SynAct today announces that the company has initiated a collaboration with William Harvey Research Instutute, Barts and London School of Medicine, Queen Mary University of London aimed to investigate pharmacogenetic... Read more

SynAct Pharma partners with Örebro University to study cardiovascular disease

SynAct Pharma AB ("SynAct") today announced the company is a partner in a research project at Örebro University to study the reduction of inflammation in vascular disease. Read more

SynAct Pharma: Interim report January-March 2021

“The first three months have indeed given a strong and convincing start of the new year to SynAct Pharma, when we continued to make significant progress on our projects and put the company in a unique p... Read more

SynAct Pharma Board and Management extend lock-up period   UK Version

SynAct Pharma AB ("SynAct") today announced all members of its board and management team have extended the lock-up period for their SynAct Pharma shares until December 31, 2021. In total the lock-up agreements... Read more

SynAct Pharma expands AP1189 BEGIN study in Rheumatoid Arthritis UK Version

Lund, Sweden, May 4, 2021. SynAct Pharma AB ("SynAct") today announced that based upon the encouraging results seen in part 1 of the phase 2 clinical study BEGIN of AP1189, the company has decided to increase... Read more

April 2021

SynAct Pharma to participate at Kempen’s virtual Life Sciences Conference

SynAct Pharma AB ("SynAct") today announced that the company will participate at the virtual meeting Kempen Life Sciences Conference - 2021 Thematic Virtual Series, on May 5. Read more

SynAct Pharma shareholders propose Marina Bozilenko as new board member

SynAct Pharma AB ("SynAct") today announced that shareholders representing more than 20 per cent of the shares and votes in the company propose Marina Bozilenko to be elected as new board member of SynAct... Read more

Notice of annual general meeting in SynAct Pharma AB

The shareholders in SynAct Pharma AB, Reg. No. 559058-4826 (“SynAct”), are hereby invited to the annual general meeting to be held on Friday 21 May 2021. Read more

SynAct strengthens IP portfolio – Receives “Intention to Grant” from the European Patent Office for a key patent covering AP1189 English version

SynAct Pharma AB ("SynAct") today announced that the European Patent Office (EPO) issued an “Intention to grant” for SynAct’s patent application covering the company’s leading drug candidate AP1189 in meth... Read more

March 2021

SynAct has initiated dosing in part 2 of the clinical Phase II study with AP1189 in Covid-19 infected patients UK version

SynAct Pharma AB ("SynAct") today announced that dosing in the second part of the exploratory clinical Phase 2 study with AP1189 in Covid-19 patients conducted under the RESOVIR collaboration has been... Read more

SynAct Pharma’s CFO and board member sell shares to cover taxes on holdings

SynAct Pharma AB (“SynAct”) today announced that board member John Haurum has sold 5,968 shares and Chief Financial Officer Henrik Stage has sold 57,000 shares in SynAct Pharma. The sales correspond to ... Read more

February 2021

Year-end Report 2020

2020-10-01 – 2020-12-31 (fourth quarter) Consolidated net sales amounted to TSEK 0 (0). The Group's profit before tax amounted to TSEK -9 786 (-11 203). The Group's earnings per share amounted to SEK -... Read more

SynAct Pharma Names James Knight as Chief Business Officer – Already published in Swedish today

SynAct Pharma AB (“SynAct”) today announced the appointment of James Knight as Chief Business Officer (CBO). He will head up business development and pipeline portfolio management and has more than 25 ... Read more

SynAct carries out a directed share issue and raises proceeds of SEK 80 million

SynAct Pharma AB (publ) (”SynAct” or ”the Company”) has, in accordance with the announcement made in a press release yesterday, successfully completed a directed share issue of 1,600,000 shares at a pr... Read more

SynAct explores the conditions for carrying out a directed share issue – English version – Published today 17.31 CET

SynAct Pharma AB (publ) (“SynAct” or “the Company”) has engaged ABG Sundal Collier AB to explore the conditions for carrying out a directed share issue of up to SEK 55 million based on an accelerated bookbui... Read more

SynAct Pharma prepares move to Nasdaq Stockholm – English version – Published today at 17.31 CET

February 4, 2021 17:31 CET The Board of Directors of SynAct Pharma AB (“SynAct Pharma” or the “Company”) has decided to evaluate the conditions and begin preparing for listing the Company’s share on ... Read more

January 2021

SynAct Pharma names Thomas Boesen as Chief Operating Officer

SynAct Pharma AB (“SynAct”) today announced the appointment of Dr. Thomas Boesen as Chief Operating Officer (COO), effective immediately. His operational role as the new COO will be to drive forward the... Read more

Published in English – already published 11:18 CET today Disclosure notice in SynAct Pharma AB

SynAct Pharma AB (“SynAct” or the “Company”) hereby announces that the Company’s shareholders TJ Biotech ApS (wholly-owned by the board member and CSO Thomas Jonassen) and Quantass ApS (owned by the CE... Read more